{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,29]],"date-time":"2026-01-29T13:04:52Z","timestamp":1769691892616,"version":"3.49.0"},"reference-count":13,"publisher":"Springer Science and Business Media LLC","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2022,6,22]]},"DOI":"10.7759\/cureus.26207","type":"journal-article","created":{"date-parts":[[2022,6,22]],"date-time":"2022-06-22T18:07:15Z","timestamp":1655921235000},"source":"Crossref","is-referenced-by-count":3,"title":["Rare Case of Reversible Pulmonary Arterial Hypertension Secondary to Cyclophosphamide and Doxorubicin Chemotherapy"],"prefix":"10.7759","author":[{"given":"Aneeqa","family":"Javed","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yelizaveta","family":"Medina","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Amber","family":"Bux","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Syeda","family":"Sahra","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Geurys","family":"Rojas-Marte","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","reference":[{"key":"ref1","doi-asserted-by":"publisher","DOI":"10.5455\/medarh.2016.70.303-307","article-title":"Pulmonary hypertension - new trends of diagnostic and therapy","volume":"70","author":"Pesto S","year":"2016","unstructured":"Pesto S, Begic Z, Prevljak S, Pecar E, Kukavica N, Begic E. Pulmonary hypertension - new trends of diagnostic and therapy. Med Arch. 2016, 70:303-7. 10.5455\/medarh.2016.70.303-307","journal-title":"Med Arch"},{"key":"ref2","article-title":"Pulmonary hypertension","volume":"114","author":"Hoeper MM","year":"2017","unstructured":"Hoeper MM, Ghofrani HA, Gr\u00fcnig E, Klose H, Olschewski H, Rosenkranz S. Pulmonary hypertension. Dtsch Arztebl Int. 2017, 114:73-84.","journal-title":"Dtsch Arztebl Int"},{"key":"ref3","doi-asserted-by":"publisher","DOI":"10.1183\/09059180.00003313","article-title":"Drug-induced pulmonary arterial hypertension: a recent outbreak","volume":"22","author":"Montani D","year":"2013","unstructured":"Montani D, Seferian A, Savale L, Simonneau G, Humbert M. Drug-induced pulmonary arterial hypertension: a recent outbreak. Eur Respir Rev. 2013, 22:244-50. 10.1183\/09059180.00003313","journal-title":"Eur Respir Rev"},{"key":"ref4","article-title":"Pulmonary arterial hypertension due to the use of amphetamines as drugs or doping (Article in Dutch)","volume":"149","author":"van Wolferen SA","year":"2005","unstructured":"van Wolferen SA, Vonk Noordegraaf A, Boonstra A, Postmus PE. Pulmonary arterial hypertension due to the use of amphetamines as drugs or doping (Article in Dutch). Ned Tijdschr Geneeskd. 2005, 149:1283-8.","journal-title":"Ned Tijdschr Geneeskd"},{"key":"ref5","doi-asserted-by":"publisher","DOI":"10.1080\/15563650.2018.1447119","article-title":"Drug-associated pulmonary arterial hypertension","volume":"56","author":"McGee M","year":"2018","unstructured":"McGee M, Whitehead N, Martin J, Collins N. Drug-associated pulmonary arterial hypertension. Clin Toxicol (Phila). 2018, 56:801-9. 10.1080\/15563650.2018.1447119","journal-title":"Clin Toxicol (Phila)"},{"key":"ref6","doi-asserted-by":"publisher","DOI":"10.1016\/j.ajpath.2014.10.021","article-title":"Chemotherapy-induced pulmonary hypertension: role of alkylating agents","volume":"185","author":"Ranchoux B","year":"2015","unstructured":"Ranchoux B, G\u00fcnther S, Quarck R, et al.. Chemotherapy-induced pulmonary hypertension: role of alkylating agents. Am J Pathol. 2015, 185:356-71. 10.1016\/j.ajpath.2014.10.021","journal-title":"Am J Pathol"},{"key":"ref7","doi-asserted-by":"publisher","DOI":"10.1177\/2324709619840375","article-title":"Pulmonary veno-occlusive disease: a rare cause of pulmonary hypertension","volume":"7","author":"Hajouli S","year":"2019","unstructured":"Hajouli S, Moustafa MA, Memoli JS. Pulmonary veno-occlusive disease: a rare cause of pulmonary hypertension. J Investig Med High Impact Case Rep. 2019, 7:2324709619840375. 10.1177\/2324709619840375","journal-title":"J Investig Med High Impact Case Rep"},{"key":"ref8","doi-asserted-by":"publisher","DOI":"10.1016\/0163-7258(90)90049-8","article-title":"Metabolism and pulmonary toxicity of cyclophosphamide","volume":"47","author":"Patel JM","year":"1990","unstructured":"Patel JM. Metabolism and pulmonary toxicity of cyclophosphamide. Pharmacol Ther. 1990, 47:137-46. 10.1016\/0163-7258(90)90049-8","journal-title":"Pharmacol Ther"},{"key":"ref9","doi-asserted-by":"publisher","DOI":"10.1124\/mol.119.115725","article-title":"Insights into doxorubicin-induced cardiotoxicity: molecular mechanisms, preventive strategies, and early monitoring","volume":"96","author":"Wenningmann N","year":"2019","unstructured":"Wenningmann N, Knapp M, Ande A, Vaidya TR, Ait-Oudhia S. Insights into doxorubicin-induced cardiotoxicity: molecular mechanisms, preventive strategies, and early monitoring. Mol Pharmacol. 2019, 96:219-32. 10.1124\/mol.119.115725","journal-title":"Mol Pharmacol"},{"key":"ref10","doi-asserted-by":"publisher","DOI":"10.1592\/phco.27.4.616","article-title":"Fatal pulmonary toxicity after a single dose of cyclophosphamide","volume":"27","author":"Gupta S","year":"2007","unstructured":"Gupta S, Mahipal A. Fatal pulmonary toxicity after a single dose of cyclophosphamide. Pharmacotherapy. 2007, 27:616-8. 10.1592\/phco.27.4.616","journal-title":"Pharmacotherapy"},{"key":"ref11","article-title":"Cyclophosphamide-induced pulmonary toxicity","volume":"7","author":"Siemann DW","year":"1986","unstructured":"Siemann DW, Macler L, Penney DP. Cyclophosphamide-induced pulmonary toxicity. Br J Cancer Suppl. 1986, 7:343-6.","journal-title":"Br J Cancer Suppl"},{"key":"ref12","doi-asserted-by":"publisher","DOI":"10.1002\/art.23303","article-title":"Immunosuppressive therapy in lupus- and mixed connective tissue disease-associated pulmonary arterial hypertension: a retrospective analysis of twenty-three cases","volume":"58","author":"Jais X","year":"2008","unstructured":"Jais X, Launay D, Yaici A, et al.. Immunosuppressive therapy in lupus- and mixed connective tissue disease-associated pulmonary arterial hypertension: a retrospective analysis of twenty-three cases. Arthritis Rheum. 2008, 58:521-31. 10.1002\/art.23303","journal-title":"Arthritis Rheum"},{"key":"ref13","doi-asserted-by":"publisher","DOI":"10.1111\/1756-185X.13001","article-title":"Pulmonary hypertension in connective tissue diseases: an update","volume":"20","author":"Aithala R","year":"2017","unstructured":"Aithala R, Alex AG, Danda D. Pulmonary hypertension in connective tissue diseases: an update. Int J Rheum Dis. 2017, 20:5-24. 10.1111\/1756-185X.13001","journal-title":"Int J Rheum Dis"}],"container-title":["Cureus"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.cureus.com\/articles\/103009-rare-case-of-reversible-pulmonary-arterial-hypertension-secondary-to-cyclophosphamide-and-doxorubicin-chemotherapy","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,2,9]],"date-time":"2024-02-09T19:37:42Z","timestamp":1707507462000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.cureus.com\/articles\/103009-rare-case-of-reversible-pulmonary-arterial-hypertension-secondary-to-cyclophosphamide-and-doxorubicin-chemotherapy"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,6,22]]},"references-count":13,"URL":"https:\/\/doi.org\/10.7759\/cureus.26207","relation":{},"ISSN":["2168-8184"],"issn-type":[{"value":"2168-8184","type":"print"}],"subject":[],"published":{"date-parts":[[2022,6,22]]}}}